FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jane Endicott

Research Profile

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Hao Shao; Shenhua Shi; Abdullahi Y Abbas; Sonja Baumli; Jane A Endicott; Peter M Fischer; David W Foley; Alison J Hole; Shiliang Huang; Frankie Lam; Xiangrui Liu; Martin Noble; Chris Pepper; Shudong Wang
Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities.
Alison J Hole; Shiliang Huang; Sonja Baumli; Jane A Endicott; Peter M Fischer; Chris Pepper; Hao Shao; Shenhua Shi; Shudong Wang; Martin E M Noble
Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
Jonas Boehringer; Colin Gordon; Eachan O D Johnson; Christina Khoudian; Edward D Lowe; Martin E M Noble; Konstantinos Paraskevopoulos; Christiane Riedinger; Dominique Smith; Jane A Endicott
Structural and functional characterization of Rpn12 identifies residues required for Rpn10 proteasome incorporation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jane Endicott (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Hao Shao; Shenhua Shi; Abdullahi Y Abbas; Sonja Baumli; Jane A Endicott; Peter M Fischer; David W Foley; Alison J Hole; Shiliang Huang; Frankie Lam; Xiangrui Liu; Martin Noble; Chris Pepper; Shudong Wang
Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities.
Journal of medicinal chemistry 2013;56(3):640-59.
2013: Alison J Hole; Shiliang Huang; Sonja Baumli; Jane A Endicott; Peter M Fischer; Chris Pepper; Hao Shao; Shenhua Shi; Shudong Wang; Martin E M Noble
Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
Journal of medicinal chemistry 2013;56(3):660-70.
2012: Jonas Boehringer; Colin Gordon; Eachan O D Johnson; Christina Khoudian; Edward D Lowe; Martin E M Noble; Konstantinos Paraskevopoulos; Christiane Riedinger; Dominique Smith; Jane A Endicott
Structural and functional characterization of Rpn12 identifies residues required for Rpn10 proteasome incorporation.
The Biochemical journal 2012;448(1):55-65.
2012: Sonja Baumli; Alison J Hole; Martin E M Noble; Lan-Zhen Wang; Jane A Endicott
The CDK9 tail determines the reaction pathway of positive transcription elongation factor b.
Structure (London, England : 1993) 2012;20(10):1788-95.
2012: Sonja Baumli; Alison J Hole; Martin E M Noble; Jane A Endicott
The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508.
ACS chemical biology 2012;7(5):811-6.
2011: Anna F Watson; Qing Xu; Yan Zhao; Karim Bennaceur; Catherine J Drummond; Jane A Endicott; Bernard T Golding; Roger J Griffin; Karen Haggerty; Junfeng Liu; Xiaohong Lu; John Lunec; James M McDonnell; David R Newell; Martin E M Noble; Charlotte H Revill; Christiane Riedinger; Ian R Hardcastle
MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones.
Bioorganic & medicinal chemistry letters 2011;21(19):5916-9.
2011: Christiane Riedinger; Martin E M Noble; David J Wright; Florian Mulks; Ian R Hardcastle; Jane A Endicott; James M McDonnell
Understanding small-molecule binding to MDM2: insights into structural effects of isoindolinone inhibitors from NMR spectroscopy.
Chemical biology & drug design 2011;77(5):301-8.
2010: Christiane Riedinger; Jonas Boehringer; Jean-Francois Trempe; Edward D Lowe; Nick R Brown; Kalle Gehring; Martin E M Noble; Colin Gordon; Jane A Endicott
Structure of Rpn10 and its interactions with polyubiquitin chains and the proteasome subunit Rpn12.
The Journal of biological chemistry 2010;285(44):33992-4003.
2010: Sonja Baumli; Jane A Endicott; Louise N Johnson
Halogen bonds form the basis for selective P-TEFb inhibition by DRB.
Chemistry & biology 2010;17(9):931-6.
2010: Karima Bettayeb; Claire Delehouze; Setha Douc-Rasy; Jane A Endicott; Hervé Galons; Alison J Hole; Nadège Loaëc; Sonja Baumli; Dianne Baunbæk; Jean Bénard; Nassima Oumata; Laurent Meijer
CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells.
Genes & cancer 2010;1(4):369-80.
2010: Aude Echalier; Jane A Endicott; Martin E M Noble
Recent developments in cyclin-dependent kinase biochemical and structural studies.
Biochimica et biophysica acta 2010;1804(3):511-9.
2009: Christiane Riedinger; Jane A Endicott
All change: protein conformation and the ubiquitination reaction cascade.
F1000 biology reports 2009;1():19.
2008: Aude Echalier; Karima Bettayeb; Yoan Ferandin; Olivier Lozach; Monique Clément; Annie Valette; François Liger; Bernard Marquet; Jonathan C Morris; Jane A Endicott; Benoît Joseph; Laurent Meijer
Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex.
Journal of medicinal chemistry 2008;51(4):737-51.
2007: Karima Bettayeb; Oscar M Tirado; Séverine Marionneau-Lambot; Yoan Ferandin; Olivier Lozach; Jonathan C Morris; Silvia Mateo-Lozano; Peter Drueckes; Christoph Schächtele; Michael H G Kubbutat; François Liger; Bernard Marquet; Benoît Joseph; Aude Echalier; Jane A Endicott; Vicente Notario; Laurent Meijer
Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases.
Cancer research 2007;67(17):8325-34.
2007: Francesco Marchetti; Kerry L Sayle; Johanne Bentley; William Clegg; Nicola J Curtin; Jane A Endicott; Bernard T Golding; Roger J Griffin; Karen Haggerty; Ross W Harrington; Veronique Mesguiche; David R Newell; Martin E M Noble; Rachel J Parsons; David J Pratt; Lan Z Wang; Ian R Hardcastle
Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2.
Organic & biomolecular chemistry 2007;5(10):1577-85.
2007: Julie P I Welburn; Julie A Tucker; Tim Johnson; Lisa Lindert; Marc Morgan; Antony Willis; Martin E M Noble; Jane A Endicott
How tyrosine 15 phosphorylation inhibits the activity of cyclin-dependent kinase 2-cyclin A.
The Journal of biological chemistry 2007;282(5):3173-81.
2007: Jean-Francois Trempe; Jane A Endicott
Structural biology: pass the protein.
Nature 2007;445(7126):375-6.
2006: David J Pratt; Johanne Bentley; Philip Jewsbury; F Thomas Boyle; Jane A Endicott; Martin E M Noble
Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.
Journal of medicinal chemistry 2006;49(18):5470-7.
2006: Roger J Griffin; Andrew Henderson; Nicola J Curtin; Aude Echalier; Jane A Endicott; Ian R Hardcastle; David R Newell; Martin E M Noble; Lan Z Wang; Bernard T Golding
Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination.
Journal of the American Chemical Society 2006;128(18):6012-3.
2006: Edward D Lowe; Na'il Hasan; Jean-Francois Trempe; Laura Fonso; Martin E M Noble; Jane A Endicott; Louise N Johnson; Nick R Brown
Structures of the Dsk2 UBL and UBA domains and their complex.
Acta crystallographica. Section D, Biological crystallography 2006;62(Pt 2):177-88.
2005: Neil Macdonald; Julie P I Welburn; Martin E M Noble; Anhco Nguyen; Michael B Yaffe; David Clynes; Jonathan G Moggs; George Orphanides; Stuart Thomson; John W Edmunds; Alison L Clayton; Jane A Endicott; Louis C Mahadevan
Molecular basis for the recognition of phosphorylated and phosphoacetylated histone h3 by 14-3-3.
Molecular cell 2005;20(2):199-211.
2005: Jean-Francois Trempe; Nick R Brown; Edward D Lowe; Colin Gordon; Iain D Campbell; Martin E M Noble; Jane A Endicott
Mechanism of Lys48-linked polyubiquitin chain recognition by the Mud1 UBA domain.
The EMBO journal 2005;24(18):3178-89.
2005: Julie P I Welburn; Jane A Endicott
Inhibition of the cell cycle with chemical inhibitors: a targeted approach.
Seminars in cell & developmental biology 2005;16(3):369-81.
2004: Ian R Hardcastle; Christine E Arris; Johanne Bentley; F Thomas Boyle; Yuzhu Chen; Nicola J Curtin; Jane A Endicott; Ashleigh E Gibson; Bernard T Golding; Roger J Griffin; Philip Jewsbury; Jerome Menyerol; Veronique Mesguiche; David R Newell; Martin E M Noble; David J Pratt; Lan Z Wang; Hayley J Whitfield
N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2.
Journal of medicinal chemistry 2004;47(15):3710-22.
2004: David J Pratt; Jane A Endicott; Martin E M Noble
The role of structure in kinase-targeted inhibitor design.
Current opinion in drug discovery & development 2004;7(4):428-36.
2004: Martin E M Noble; Jane A Endicott; Louise N Johnson
Protein kinase inhibitors: insights into drug design from structure.
Science (New York, N.Y.) 2004;303(5665):1800-5.
2003: Kerry L Sayle; Johanne Bentley; F Thomas Boyle; A Hilary Calvert; Yuzhu Cheng; Nicola J Curtin; Jane A Endicott; Bernard T Golding; Ian R Hardcastle; Philip Jewsbury; Veronique Mesguiche; David R Newell; Martin E M Noble; Rachel J Parsons; David J Pratt; Lan Z Wang; Roger J Griffin
Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2.
Bioorganic & medicinal chemistry letters 2003;13(18):3079-82.
2003: Veronique Mesguiche; Rachel J Parsons; Christine E Arris; Johanne Bentley; F Thomas Boyle; Nicola J Curtin; Thomas G Davies; Jane A Endicott; Ashleigh E Gibson; Bernard T Golding; Roger J Griffin; Philip Jewsbury; Louise N Johnson; David R Newell; Martin E M Noble; Lan Z Wang; Ian R Hardcastle
4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2.
Bioorganic & medicinal chemistry letters 2003;13(2):217-22.
2002: Thomas G Davies; Johanne Bentley; Christine E Arris; F Thomas Boyle; Nicola J Curtin; Jane A Endicott; Ashleigh E Gibson; Bernard T Golding; Roger J Griffin; Ian R Hardcastle; Philip Jewsbury; Louise N Johnson; Veronique Mesguiche; David R Newell; Martin E M Noble; Julie A Tucker; Lan Wang; Hayley J Whitfield
Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.
Nature structural biology 2002;9(10):745-9.
2002: Ashleigh E Gibson; Christine E Arris; Johanne Bentley; F Thomas Boyle; Nicola J Curtin; Thomas G Davies; Jane A Endicott; Bernard T Golding; Sharon Grant; Roger J Griffin; Philip Jewsbury; Louise N Johnson; Veronique Mesguiche; David R Newell; Martin E M Noble; Julie A Tucker; Hayley J Whitfield
Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives.
Journal of medicinal chemistry 2002;45(16):3381-93.
2002: Thomas G Davies; David J Pratt; Jane A Endicott; Louise N Johnson; Martin E M Noble
Structure-based design of cyclin-dependent kinase inhibitors.
Pharmacology & therapeutics 2002;93(2-3):125-33.
2002: Louise N Johnson; Erika De Moliner; Nick R Brown; Haiwei Song; David Barford; Jane A Endicott; Martin E M Noble
Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2.
Pharmacology & therapeutics 2002;93(2-3):113-24.
2001: AM Lawrie; Paula Tito; H Hernandez; Nick R Brown; Carol V Robinson; Jane A Endicott; Martin E M Noble; Louise N Johnson
Xenopus phospho-CDK7/cyclin H expressed in baculoviral-infected insect cells.
Protein expression and purification 2001;23(2):252-60.
2001: Thomas G Davies; P Tunnah; Laurent Meijer; Doris Marko; Gerhard Eisenbrand; Jane A Endicott; Martin E M Noble
Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate.
Structure (London, England : 1993) 2001;9(5):389-97.
2000: Christine E Arris; F Thomas Boyle; A Hilary Calvert; Nicola J Curtin; Jane A Endicott; E F Garman; Ashleigh E Gibson; Bernard T Golding; S Grant; Roger J Griffin; Philip Jewsbury; Louise N Johnson; AM Lawrie; David R Newell; Martin E M Noble; Edward A Sausville; R Schultz; W Yu
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
Journal of medicinal chemistry 2000;43(15):2797-804.
1999: Jane A Endicott; Martin E M Noble; Julie A Tucker
Cyclin-dependent kinases: inhibition and substrate recognition.
Current opinion in structural biology 1999;9(6):738-44.
1999: Nick R Brown; Martin E M Noble; Jane A Endicott; Louise N Johnson
The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases.
Nature cell biology 1999;1(7):438-43.
1999: R Hoessel; S Leclerc; Jane A Endicott; M E Nobel; AM Lawrie; P Tunnah; Maryse Leost; E Damiens; D Marie; Doris Marko; Ellen Niederberger; W Tang; Gerhard Eisenbrand; Laurent Meijer
Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases.
Nature cell biology 1999;1(1):60-7.
1999: Martin E M Noble; Jane A Endicott
Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies.
Pharmacology & therapeutics 1999;82(2-3):269-78.
1999: Nick R Brown; Martin E M Noble; AM Lawrie; M C Morris; P Tunnah; G Divita; Louise N Johnson; Jane A Endicott
Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity.
The Journal of biological chemistry 1999;274(13):8746-56.
1998: Jane A Endicott; Martin E M Noble
Structural principles in cell-cycle control: beyond the CDKs.
Structure (London, England : 1993) 1998;6(5):535-41.
1997: Martin E M Noble; Jane A Endicott; Nick R Brown; Louise N Johnson
The cyclin box fold: protein recognition in cell-cycle and transcription control.
Trends in biochemical sciences 1997;22(12):482-7.
1997: AM Lawrie; Martin E M Noble; P Tunnah; Nick R Brown; Louise N Johnson; Jane A Endicott
Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2.
Nature structural biology 1997;4(10):796-801.
1995: Nick R Brown; Martin E M Noble; Jane A Endicott; Elspeth F Garman; S Wakatsuki; E Mitchell; B Rasmussen; Tim Hunt; Louise N Johnson
The crystal structure of cyclin A.
Structure (London, England : 1993) 1995;3(11):1235-47.
1995: Jane A Endicott; Martin E M Noble; Elspeth F Garman; N Brown; B Rasmussen; Paul Nurse; Louise N Johnson
The crystal structure of p13suc1, a p34cdc2-interacting cell cycle control protein.
The EMBO journal 1995;14(5):1004-14.
1994: Jane A Endicott; Paul Nurse; Louise N Johnson
Mutational analysis supports a structural model for the cell cycle protein kinase p34.
Protein engineering 1994;7(2):243-53.